Sodium Zirconium Cyclosilicate has 12 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Atorvastatin, Dabigatran, Furosemide. Patients taking Sodium Zirconium Cyclosilicate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 12
- Moderate
- 4
- Minor
- 4
Moderate (4)
- Sodium Zirconium Cyclosilicate + Atorvastatin— LOKELMA increases systemic exposure to atorvastatin by elevating gastric pH. Separate administration by at least 2 hours…
- Sodium Zirconium Cyclosilicate + Dabigatran— LOKELMA decreases systemic exposure to dabigatran by elevating gastric pH. Separate administration by at least 2 hours.
- Sodium Zirconium Cyclosilicate + Furosemide— LOKELMA increases systemic exposure to furosemide by elevating gastric pH. Separate administration by at least 2 hours.
- Sodium Zirconium Cyclosilicate + Tacrolimus— LOKELMA decreases systemic exposure to tacrolimus by elevating gastric pH. Separate administration by at least 2 hours.
Minor (4)
- Sodium Zirconium Cyclosilicate + Cyclosporine— In vivo testing showed no clinically meaningful interaction between LOKELMA and cyclosporine.
- Sodium Zirconium Cyclosilicate + Glipizide— In vivo testing showed no clinically significant changes in glipizide exposure when co-administered with LOKELMA.
- Sodium Zirconium Cyclosilicate + Levothyroxine— In vivo testing showed no clinically significant changes in levothyroxine exposure when co-administered with LOKELMA.
- Sodium Zirconium Cyclosilicate + Losartan— In vivo testing showed no clinically significant changes in losartan exposure when co-administered with LOKELMA.